Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer

Agnieszka K. Witkiewicz, Nicholas A. Borja, Jorge Franco, Jonathan R. Brody, Charles J. Yeo, John Mansour, Michael A. Choti, Peter McCue, Erik S. Knudsen

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDA) harbors an exceedingly poor prognosis, and is generally considered a therapy-recalcitrant disease due to poor response to conventional chemotherapy coupled with non-actionable genetic drivers (e.g. KRAS mutations). However, PDA frequently loses p16ink4a, thereby leading to deregulation of CDK4/6. Surprisingly, in established cell models and xenografts, CDK4/6 inhibition has a modest effect on proliferation and resistance develops rapidly. To determine if such weak response was an intrinsic feature of PDA, we developed primary tumor explants that maintain the tumor environment and recapitulate feuture of primary PDA. The CDK4/6 inhibitor PD-0332991 was highly efficient at suppressing proliferation in 14 of the 15 explants. In the single resistant explant, we identified the rare loss of the RB tumor suppressor as the basis for resistance. Patient-derived xenografts (PDXs) were developed in parallel, and unlike the xenografts emerging from established cell lines, the PDXs maintained the histoarchitecture of the primary tumor. These PDXs were highly sensitive to CDK4/6 inhibition, yielding a complete suppression of PDA proliferation. Together, these data indicate that primary PDA is sensitive to CDK4/6 inhibition, that specific biomarkers can delineate intrinsic resistance, and that established cell line models may not represent an adequate means for evaluating therapeutic sensitivities.

Original languageEnglish (US)
Pages (from-to)15788-15801
Number of pages14
JournalOncotarget
Volume6
Issue number18
StatePublished - 2015

Fingerprint

Pancreatic Neoplasms
Heterografts
Adenocarcinoma
Neoplasms
Cell Line
Biomarkers
Drug Therapy
Mutation
Therapeutics

Keywords

  • CDk4/6
  • Pancreatic cancer
  • Patient-derived xenograft
  • PD-0332991
  • Tumor explant

ASJC Scopus subject areas

  • Oncology

Cite this

Witkiewicz, A. K., Borja, N. A., Franco, J., Brody, J. R., Yeo, C. J., Mansour, J., ... Knudsen, E. S. (2015). Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. Oncotarget, 6(18), 15788-15801.

Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. / Witkiewicz, Agnieszka K.; Borja, Nicholas A.; Franco, Jorge; Brody, Jonathan R.; Yeo, Charles J.; Mansour, John; Choti, Michael A.; McCue, Peter; Knudsen, Erik S.

In: Oncotarget, Vol. 6, No. 18, 2015, p. 15788-15801.

Research output: Contribution to journalArticle

Witkiewicz, AK, Borja, NA, Franco, J, Brody, JR, Yeo, CJ, Mansour, J, Choti, MA, McCue, P & Knudsen, ES 2015, 'Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer', Oncotarget, vol. 6, no. 18, pp. 15788-15801.
Witkiewicz, Agnieszka K. ; Borja, Nicholas A. ; Franco, Jorge ; Brody, Jonathan R. ; Yeo, Charles J. ; Mansour, John ; Choti, Michael A. ; McCue, Peter ; Knudsen, Erik S. / Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. In: Oncotarget. 2015 ; Vol. 6, No. 18. pp. 15788-15801.
@article{f96225b076cc445592dbfcc634ea7216,
title = "Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer",
abstract = "Pancreatic ductal adenocarcinoma (PDA) harbors an exceedingly poor prognosis, and is generally considered a therapy-recalcitrant disease due to poor response to conventional chemotherapy coupled with non-actionable genetic drivers (e.g. KRAS mutations). However, PDA frequently loses p16ink4a, thereby leading to deregulation of CDK4/6. Surprisingly, in established cell models and xenografts, CDK4/6 inhibition has a modest effect on proliferation and resistance develops rapidly. To determine if such weak response was an intrinsic feature of PDA, we developed primary tumor explants that maintain the tumor environment and recapitulate feuture of primary PDA. The CDK4/6 inhibitor PD-0332991 was highly efficient at suppressing proliferation in 14 of the 15 explants. In the single resistant explant, we identified the rare loss of the RB tumor suppressor as the basis for resistance. Patient-derived xenografts (PDXs) were developed in parallel, and unlike the xenografts emerging from established cell lines, the PDXs maintained the histoarchitecture of the primary tumor. These PDXs were highly sensitive to CDK4/6 inhibition, yielding a complete suppression of PDA proliferation. Together, these data indicate that primary PDA is sensitive to CDK4/6 inhibition, that specific biomarkers can delineate intrinsic resistance, and that established cell line models may not represent an adequate means for evaluating therapeutic sensitivities.",
keywords = "CDk4/6, Pancreatic cancer, Patient-derived xenograft, PD-0332991, Tumor explant",
author = "Witkiewicz, {Agnieszka K.} and Borja, {Nicholas A.} and Jorge Franco and Brody, {Jonathan R.} and Yeo, {Charles J.} and John Mansour and Choti, {Michael A.} and Peter McCue and Knudsen, {Erik S.}",
year = "2015",
language = "English (US)",
volume = "6",
pages = "15788--15801",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "18",

}

TY - JOUR

T1 - Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer

AU - Witkiewicz, Agnieszka K.

AU - Borja, Nicholas A.

AU - Franco, Jorge

AU - Brody, Jonathan R.

AU - Yeo, Charles J.

AU - Mansour, John

AU - Choti, Michael A.

AU - McCue, Peter

AU - Knudsen, Erik S.

PY - 2015

Y1 - 2015

N2 - Pancreatic ductal adenocarcinoma (PDA) harbors an exceedingly poor prognosis, and is generally considered a therapy-recalcitrant disease due to poor response to conventional chemotherapy coupled with non-actionable genetic drivers (e.g. KRAS mutations). However, PDA frequently loses p16ink4a, thereby leading to deregulation of CDK4/6. Surprisingly, in established cell models and xenografts, CDK4/6 inhibition has a modest effect on proliferation and resistance develops rapidly. To determine if such weak response was an intrinsic feature of PDA, we developed primary tumor explants that maintain the tumor environment and recapitulate feuture of primary PDA. The CDK4/6 inhibitor PD-0332991 was highly efficient at suppressing proliferation in 14 of the 15 explants. In the single resistant explant, we identified the rare loss of the RB tumor suppressor as the basis for resistance. Patient-derived xenografts (PDXs) were developed in parallel, and unlike the xenografts emerging from established cell lines, the PDXs maintained the histoarchitecture of the primary tumor. These PDXs were highly sensitive to CDK4/6 inhibition, yielding a complete suppression of PDA proliferation. Together, these data indicate that primary PDA is sensitive to CDK4/6 inhibition, that specific biomarkers can delineate intrinsic resistance, and that established cell line models may not represent an adequate means for evaluating therapeutic sensitivities.

AB - Pancreatic ductal adenocarcinoma (PDA) harbors an exceedingly poor prognosis, and is generally considered a therapy-recalcitrant disease due to poor response to conventional chemotherapy coupled with non-actionable genetic drivers (e.g. KRAS mutations). However, PDA frequently loses p16ink4a, thereby leading to deregulation of CDK4/6. Surprisingly, in established cell models and xenografts, CDK4/6 inhibition has a modest effect on proliferation and resistance develops rapidly. To determine if such weak response was an intrinsic feature of PDA, we developed primary tumor explants that maintain the tumor environment and recapitulate feuture of primary PDA. The CDK4/6 inhibitor PD-0332991 was highly efficient at suppressing proliferation in 14 of the 15 explants. In the single resistant explant, we identified the rare loss of the RB tumor suppressor as the basis for resistance. Patient-derived xenografts (PDXs) were developed in parallel, and unlike the xenografts emerging from established cell lines, the PDXs maintained the histoarchitecture of the primary tumor. These PDXs were highly sensitive to CDK4/6 inhibition, yielding a complete suppression of PDA proliferation. Together, these data indicate that primary PDA is sensitive to CDK4/6 inhibition, that specific biomarkers can delineate intrinsic resistance, and that established cell line models may not represent an adequate means for evaluating therapeutic sensitivities.

KW - CDk4/6

KW - Pancreatic cancer

KW - Patient-derived xenograft

KW - PD-0332991

KW - Tumor explant

UR - http://www.scopus.com/inward/record.url?scp=84937851216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937851216&partnerID=8YFLogxK

M3 - Article

C2 - 26158861

AN - SCOPUS:84937851216

VL - 6

SP - 15788

EP - 15801

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 18

ER -